This prospective national multicenter observational and interventional study aims to assess the longitudinal disease trajectory of patients with oligometastatic disease (OMD) who receive local metastasis-directed therapy. Patients with any category of OMD from any non-hematological cancer are eligible for inclusion. Local ablative therapy (LAT) includes surgical metastasectomy, radiotherapy, thermal ablation, and electroporations.
The primary objective is to assess the time to failure of LAT strategy in patients with OMD from any primary cancer treated with all LAT modalities.
Histology or cytology proven non-haematological cancer
Stage IV disease
ECOG performance status ≤ 2
Life expectancy > 6 months
Pregnancy
Diffuse cancer disease, which cannot be locally ablated, i.e., leptomeningeal carcinomatosis, malignant pleural effusions, lymphangitic carcinomatosis, or peritoneal carcinomatosis
If LAT is deemed unsafe by the MDT (e.g., tumor perforation of hollow organs)
The size of the target is limited by the ability to safely deliver locally ablative doses to the metastatic lesions. Generally, an upper limit of 5 cm is recommended
Gitte Fredberg Persson MD PhD
Lead sponsor
Herlev Hospital
Sponsor institution